Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tuvusertib (M1774)
Tuvusertib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A, Arm 1: Tuvusertib with Niraparib | EXPERIMENTAL | In Part A, participants will be randomized to one of 2 arms to receive tuvusertib in combination with either niraparib or lartesertib. |
| Part A, Arm 2: Tuvusertib with Lartesertib | EXPERIMENTAL | In Part A, participants will be randomized to one of 2 arms to receive tuvusertib in combination with either niraparib or lartesertib. |
| Part B (dose optimization), dosing regimen 1 :Tuvusertib+Niraparib or Tuvusertib +Lartesertib | EXPERIMENTAL | In Part B, the most favorable combination treatment from Part A will be further explored at 2 different dosing regimens and compared to tuvusertib monotherapy. |
| Part B (dose optimization), dosing regimen 2: Tuvusertib + Niraparib or Tuvusertib + Lartesertib | EXPERIMENTAL | In Part B, the most favorable combination treatment from Part A will be further explored at 2 different dosing regimens and compared to tuvusertib monotherapy. |
| Part B: Tuvusertib Monotherapy | EXPERIMENTAL | In Part B, the most favorable combination treatment from Part A will be further explored at 2 different dosing regimens and compared to tuvusertib monotherapy. |
| Name | Type | Description |
|---|---|---|
| Tuvusertib (M1774) | DRUG | Tuvusertib will be administered orally. |
| Niraparib | DRUG | Niraparib will be administered orally. If selected from Part A, Niraparib will be administered orally in combination with Tuvusertib. |
| Lartesertib (M4076) | DRUG | Lartesertib will be administered orally. If selected from Part A, Lartesertib will be administered orally in combination with Tuvusertib |
Inclusion Criteria: * Histologically or cytologically confirmed high grade serous or high grade endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer that is recurrent. * Participants whose tumor carries germline or somatic deleterious or suspected deleterious mutations in the gene...
Top 20 of 59 competitors
Tuvusertib is an investigational small molecule being studied for the treatment of epithelial ovarian cancer. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Tuvusertib is a small molecule being evaluated in combination with other agents for ovarian cancer. Its specific molecular target is not disclosed in the available information, so its mechanism of action is not described here.
Tuvusertib is being developed by Merck & Company, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol MRK.
Tuvusertib is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency for the treatment of ovarian cancer.
Tuvusertib is being studied in a Phase 2 clinical trial with the identifier NCT06433219. The trial, titled 'Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)', is active but not recruiting and has an enrollment of 63 participants.
Yes, Tuvusertib is also known as M1774. Both names refer to the same investigational drug being developed by Merck & Company, Inc. for the treatment of ovarian cancer.